Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

COMPASS Pathways Plc - American Depository Shares (NQ:CMPS)

6.190 +0.480 (+8.41%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about COMPASS Pathways Plc - American Depository Shares

< Previous 1 2 3 4 Next >
News headline image
Compass Pathways to Participate in TD Cowen 45th Annual Health Care Conference
From Compass Pathways plc
Via Business Wire
Washington State Bills Seek to Legalize Psychedelics for Therapeutic Use
Via Investor Brand Network
News headline image
Compass Pathways to announce fourth quarter and year-end financial results on February 27th, 2025
From Compass Pathways plc
Via Business Wire
News headline image
Compass Pathways to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference
From Compass Pathways plc
Via Business Wire
News headline image
Compass Pathways Appoints Steve Levine, M.D., as Chief Patient Officer
From Compass Pathways plc
Via Business Wire
News headline image
Compass Pathways Announces Pricing of Underwritten Offering
From Compass Pathways plc
Via Business Wire
News headline image
Compass Pathways to Be Added to the NASDAQ Biotechnology Index (NBI)
From Compass Pathways plc
Via Business Wire
News headline image
Compass Pathways to Participate in December Investor Conferences
From Compass Pathways plc
Via Business Wire
News headline image
Compass Pathways Announces Third Quarter 2024 Financial Results and Business Updates
From Compass Pathways plc
Via Business Wire
News headline image
Compass Pathways to Announce Third Quarter Financial Results on October 31, 2024
From Compass Pathways plc
Via Business Wire
News headline image
Compass Pathways to Participate in Cowen Psychedelics and Novel Mechanisms in Neuropsychiatry Summit
From Compass Pathfinder Limited
Via Business Wire
The Next Great Biotech Boom Has Arrived
EQNX::TICKER_START (NYSE:JNJ),(NASDAQ:CMPS),(NASDAQ:MNMD),(NASDAQ:ATAI),(NYSE:ABBV) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Compass Pathways appoints Teri Loxam as Chief Financial Officer
From Compass Pathways
Via GlobeNewswire
News headline image
Study results of psilocybin treatment in bipolar II depression published in JAMA Psychiatry
Believed to be first ever psilocybin clinical trial for treatment of bipolar II depression 
From Compass Pathways
Via GlobeNewswire
How Psychedelic-Based Therapeutics Are Advancing in Treating Generalized Anxiety Disorder (GAD) Condition
EQNX::TICKER_START (NYSE:CYBN),(NASDAQ:CMPS),(NASDAQ:MNMD),(NASDAQ:SEEL),(NASDAQ:ATAI) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
COMPASS Pathways Announces Third Quarter 2023 Financial Results and Business Highlights
From COMPASS Pathways
Via GlobeNewswire
News headline image
COMPASS Pathways announces CFO transition
From COMPASS Pathways
Via GlobeNewswire
The Promise Of Psilocybin When It Comes To Mental Health, And How COMPASS Pathways (NASDAQ: CMPS) Is Advancing It
By Faith Ashmore, Benzinga 
Via TheNewswire.com
How COMPASS Pathways Is Leveraging AI To Revolutionize The Mental Healthcare Space
By Faith Ashmore, Benzinga 
Via TheNewswire.com
Topics Artificial Intelligence
One Year Into Kabir Nath’s Leadership, Compass Pathways’ (NASDAQ: CMPS) Phase 3 Trial For Innovative Treatment Resistant Depression Progressing
By Faith Ashmore, Benzinga 
Via TheNewswire.com
The Breakthrough Therapy Aiming To Solve The World’s Mental Health Crisis
EQNX::TICKER_START (NYSE:JNJ),(NYSE:ABBV),(NASDAQ:ATAI),(NASDAQ:CMPS),(NASDAQ:MNMD) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Economy
Global Psychedelic Therapeutics Market Size Expected To Reach $13.29 Billion By The Year 2031
EQNX::TICKER_START (NYSE:CYBN),NEO:CYBN),(NASDAQ:CMPS),(NASDAQ:MNMD),(NASDAQ:SEEL),(OTCQX:NUMIF) EQNX::TICKER_END 
Via FinancialNewsMedia
AMA Issues Details On First Psychedelics Therapy CPT Code – Thanks To These Psychedelic-Focused Mental Healthcare Companies
By Rachael Green, Benzinga 
Via TheNewswire.com
Largest Phase 3 Clinical Trial on Psilocybin Gets Underway
Via Investor Brand Network
News headline image
COMPASS Pathways Announces First Quarter 2023 Financial Results and Business Highlights
From COMPASS Pathways
Via GlobeNewswire
News headline image
American Medical Association to Issue First New Code for Psychedelic Therapies
COMPASS Pathways and MAPS PBC submitted joint application for new code to facilitate access to psychedelic therapy in the US, if approved 
From COMPASS Pathways
Via GlobeNewswire
Compass Pathways Plc (NASDAQ: CMPS) Highlighted for Surprising Price Action
Via Investor Brand Network
News headline image
COMPASS Pathways Announces Fourth Quarter and Year-End 2022 Financial Results and Business Highlights
From COMPASS Pathways
Via GlobeNewswire
Psychedelic-Derived Medicines for Neurologic Conditions Fueling Large Revenue Growth in Projected $4 Billion Dollar Industry
EQNX::TICKER_START (OTCQB:LOBEF),(NASDAQ:ATAI),(NASDAQ:CMPS),(NYSE:CYBN),(NASDAQ:MNMD) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Economy
News headline image
COMPASS Pathways Announces Third Quarter 2022 Financial Results and Business Highlights
From COMPASS Pathways
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.